4/10
04:22 pm
sndx
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum [Yahoo! Finance]
Low
Report
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum [Yahoo! Finance]
4/10
04:05 pm
sndx
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Low
Report
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
4/8
07:18 am
sndx
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session [Yahoo! Finance]
Medium
Report
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session [Yahoo! Finance]
4/8
07:00 am
sndx
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Medium
Report
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
4/5
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/28
11:39 am
sndx
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA [Yahoo! Finance]
Low
Report
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA [Yahoo! Finance]
3/28
07:09 am
sndx
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia [Yahoo! Finance]
3/28
07:00 am
sndx
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Low
Report
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
3/27
08:08 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.
3/26
04:18 pm
sndx
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia [Yahoo! Finance]
Medium
Report
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia [Yahoo! Finance]
3/26
04:05 pm
sndx
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Medium
Report
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
3/20
12:31 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
3/18
07:09 am
sndx
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer [Yahoo! Finance]
Medium
Report
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer [Yahoo! Finance]
3/18
07:00 am
sndx
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Medium
Report
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
3/13
09:22 am
sndx
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation [Yahoo! Finance]
3/3
08:50 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2/28
02:29 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $41.00 price target on the stock.
2/27
04:10 pm
sndx
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update [Yahoo! Finance]
2/27
04:05 pm
sndx
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Low
Report
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
2/26
11:03 am
sndx
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Low
Report
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
2/26
07:07 am
sndx
Syndax Announces Participation at Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Syndax Announces Participation at Two Upcoming Investor Conferences [Yahoo! Finance]
2/26
07:00 am
sndx
Syndax Announces Participation at Two Upcoming Investor Conferences
Medium
Report
Syndax Announces Participation at Two Upcoming Investor Conferences
2/20
04:05 pm
sndx
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
Low
Report
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
2/2
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)